Evidence map›Paper›PMID 39738247›Full record

ArticleScientific reports2024

SOCS domain targets ECM assembly in lung fibroblasts and experimental lung fibrosis.

Carina Magdaleno, Daniel J Tschumperlin, Narendiran Rajasekaran, Archana Varadaraj

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Exosomes are specialized vehicles to induce fibronectin assembly.bioRxiv : the preprint server for biology · 2025
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Carina MagdalenoDepartment of Chemistry and Biochemistry, Northern Arizona University, Flagstaff, AZ, USA.
Daniel J TschumperlinDepartment of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Narendiran RajasekaranDepartment of Chemistry and Biochemistry, Northern Arizona University, Flagstaff, AZ, USA. miranaren@gmail.com.
Archana VaradarajDepartment of Chemistry and Biochemistry, Northern Arizona University, Flagstaff, AZ, USA. archana.varadaraj@nau.edu.

Funding

SSCIMA: Integrating Analysis of Socio-economic Sub-population Dynamics to Improve Spatial Models of Infectious DiseaseU54MD012388 · NIMHD · NORTHERN ARIZONA UNIVERSITY · PI Julie A. Baldwin · 2017 to 2026
$49.7M
SOCS domain-mediated fibronectin matrix degradation on fibrosis reversalR15HL154051 · NHLBI · NORTHERN ARIZONA UNIVERSITY · PI INGRAM, JANI CHERI · 2021 to 2021
$469k
NHLBI NIH HHS R15 HL154051NIH HHS 1R15HL154051-01A1NIMHD NIH HHS U54 MD012388Southwest Health Equity Research Collaborative U54MD012388
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal disease defined by a progressive decline in lung function due to scarring and accumulation of extracellular matrix (ECM) proteins. The SOCS (Suppressor Of Cytokine Signaling) domain is a 40 amino acid conserved domain known to form a functional ubiquitin ligase complex targeting the Von Hippel Lindau (VHL) protein for proteasomal degradation. Here we show that the SOCS conserved domain operates as a molecular tool, to disrupt collagen and fibronectin fibrils in the ECM associated with fibrotic lung myofibroblasts. Our results demonstrate that fibroblasts differentiated using TGFβ, followed by transduction with the SOCS domain, exhibit significantly reduced levels of the contractile myofibroblast-marker, α-SMA. Furthermore, in support of its role to retard differentiation, we find that lung fibroblasts expressing the SOCS domain present with significantly reduced levels of α-SMA and fibrillar fibronectin after differentiation with TGFβ. We show that adenoviral delivery of the SOCS domain in the fibrotic phase of experimental lung fibrosis in mice, significantly reduces collagen accumulation in disease lungs. These data underscore a novel function for the SOCS domain and its potential in ameliorating pathologic matrix deposition in lung fibroblasts and experimental lung fibrosis.

Indexed as

Extracellular MatrixFibroblastsLungSuppressor of Cytokine Signaling ProteinsActinsAnimalsCell DifferentiationCollagenDisease Models, AnimalFibronectinsHumansMiceMyofibroblastsProtein DomainsPulmonary FibrosisTransforming Growth Factor betaActinsCollagenFibronectinsSuppressor of Cytokine Signaling ProteinsTransforming Growth Factor betaECMFibroblastFibronectinMyofibroblastSOCS domain

Identifiers

PMID39738247
PMCPMC11686354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.